ProfileGDS5678 / 1416756_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 89% 87% 89% 88% 90% 90% 89% 90% 89% 90% 89% 90% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.796388
GSM967853U87-EV human glioblastoma xenograft - Control 27.053189
GSM967854U87-EV human glioblastoma xenograft - Control 36.7777687
GSM967855U87-EV human glioblastoma xenograft - Control 47.2472989
GSM967856U87-EV human glioblastoma xenograft - Control 56.9985188
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.9597190
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.9304190
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.9075489
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.1500590
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1315389
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.1529490
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.0377589
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.1358390
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.2578490